

**REVOCATION OF POWER OF ATTORNEY
WITH NEW POWER OF ATTORNEY
AND
CHANGE OF CORRESPONDENCE
ADDRESS**

Application Number	10/727,655
Filing Date	December 05, 2003
First Named Inventor	SZELENYI, ISTVAN, et al.
Title	COMBINATIONS OF RETIGABINE AND SODIUM CHANNEL INHIBITORS OR SODIUM CHANNEL- INFLUENCING ACTIVE COMPOUNDS FOR TREATING PAINS
Art Unit	1614
Examiner Name	Kwon, Brian Yong S.
Attorney Docket Number	081117-0126

I hereby revoke all previous powers of attorney given in the above-identified application.

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint the practitioners associated with the Customer Number:

41552

☒ Please change the correspondence address for the above-identified application to:

☒ The address associated with Customer Number:

41552

OR


<input type="checkbox"/> Firm or Individual Name				
Address				
City		State		Zip
Country				
Telephone		Email		

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature		Date	Jun 18-08
Name	Eileen C. Pruette	Telephone	949 461-6219
Title and Company	Executive Vice President, General Counsel VALEANT PHARMACEUTICALS INTERNATIONAL, INC.		

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ *Total of _____ forms are submitted.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Valeant Pharmaceuticals North America (formerly known as Xcel Pharmaceuticals, Inc.)Application No./Patent No.: 10/727,655 Filed/Issue Date: December 5, 2003Entitled: Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating painsValeant Pharmaceuticals North America, a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

A ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: inventors To: VIATRIS GMBH & CO. KG
The document was recorded in the United States Patent and Trademark Office at
Reel 015133, Frame 0421, or for which a copy thereof is attached.
2. From: VIATRIS GMBH & CO. KG To: XCEL PHARMACEUTICALS, INC.
The document was recorded in the United States Patent and Trademark Office at
Reel 015212, Frame 0443, or for which a copy thereof is attached.
3. From: XCEL PHARMACEUTICALS, INC. To: VALEANT PHARMACEUTICALS NORTH AMERICA
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Robert Chai-Onn Signature Feb 17, 2006 Date
Robert Chai-Onn Printed or Typed Name (714) 545-0100 Telephone Number
Vice President, Assistant Secretary Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.